semaglutide brasil Eurofarma Launches Program for Obesity and Diabetes in Brazil A patente da semaglutida, princípio

[cited 2021 Feb 05]

Physician-supervised GLP-1 programs delivering real, durable weight loss, without the crash

Streubel-Gallasch L, Giusti V, Sandre M et al (2021) Parkinsons disease-associated LRRK2 interferes with astrocyte-mediated alpha-synuclein clearance

As results from clinical trials have consistently shown a homocysteine-lowering effect, NAC at a dose of at least 800 mg per day could be recommended to people with elevated homocysteine levels

Morin-Papunen L, Rautio K, Ruokonen A, Hedberg P, Puukka M, Tapanainen JS

GLP-1 medications slow gastric emptying, which is a common reason nausea shows up, particularly when starting a new dose